Parathyroid Hormone (PTH) With Alendronate for Osteoporosis [clinicaltrials:NCT00005006]
Parathyroid Hormone (PTH) With Alendronate for Osteoporosis [clinicaltrials:NCT00005006]
Bio2RDF identifier
NCT00005006
Bio2RDF namespace
clinicaltrials
Bio2RDF uri
http://bio2rdf.org/clinicaltrials:NCT00005006
identifiers.org URI
arm group [clinicaltrials_vocabulary:arm-group]
authority [clinicaltrials_vocabulary:authority]
brief summary [clinicaltrials_vocabulary:brief-summary]
This study investigates ...... plus daily
alendronate.
brief title [clinicaltrials_vocabulary:brief-title]
Parathyroid Hormone (PTH) With Alendronate for Osteoporosis
completion date [clinicaltrials_vocabulary:completion-date]
2006-12-01T00:00:00Z
condition [clinicaltrials_vocabulary:condition]
condition browse [clinicaltrials_vocabulary:condition-browse]
condition mesh [clinicaltrials_vocabulary:condition-mesh]
country [clinicaltrials_vocabulary:country]
detailed description [clinicaltrials_vocabulary:detailed-description]
Osteoporosis is a signi ...... daily or weekly alendronate.
download date [clinicaltrials_vocabulary:download-date]
ClinicalTrials.gov processed this data on August 10, 2015
eligibility [clinicaltrials_vocabulary:eligibility]
enrollment [clinicaltrials_vocabulary:enrollment]
firstreceived date [clinicaltrials_vocabulary:firstreceived-date]
2000-03-24T00:00:00Z
has expanded access [clinicaltrials_vocabulary:has-expanded-access]
intervention [clinicaltrials_vocabulary:intervention]
intervention browse [clinicaltrials_vocabulary:intervention-browse]
is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]
keyword [clinicaltrials_vocabulary:keyword]
Alendronate
Anabolic agent
Bone formation
Bone turnover
Cyclical therapy
Osteoporosis
Parathyroid hormone
lastchanged date [clinicaltrials_vocabulary:lastchanged-date]
2008-03-04T00:00:00Z
lead sponsor [clinicaltrials_vocabulary:lead-sponsor]
location [clinicaltrials_vocabulary:location]
nct id [clinicaltrials_vocabulary:nct-id]
NCT00005006
number of arms [clinicaltrials_vocabulary:number-of-arms]
official title [clinicaltrials_vocabulary:official-title]
Cyclical vs Daily Continuous PTH in Combination With Alendronate vs Alendronate Alone
org study id [clinicaltrials_vocabulary:org-study-id]
P50 AR39191
overall official [clinicaltrials_vocabulary:overall-official]
overall status [clinicaltrials_vocabulary:overall-status]
oversight [clinicaltrials_vocabulary:oversight]
phase [clinicaltrials_vocabulary:phase]
primary completion date [clinicaltrials_vocabulary:primary-completion-date]
2003-02-01T00:00:00Z
responsible party [clinicaltrials_vocabulary:responsible-party]
secondary id [clinicaltrials_vocabulary:secondary-id]
source [clinicaltrials_vocabulary:source]
start date [clinicaltrials_vocabulary:start-date]
1987-09-01T00:00:00Z
study design [clinicaltrials_vocabulary:study-design]
study type [clinicaltrials_vocabulary:study-type]
url [clinicaltrials_vocabulary:url]
verification date [clinicaltrials_vocabulary:verification-date]
2008-03-01T00:00:00Z
identifier
clinicaltrials:NCT00005006
title
Parathyroid Hormone (PTH) With Alendronate for Osteoporosis
@en
type
label
Parathyroid Hormone (PTH) With Alendronate for Osteoporosis [clinicaltrials:NCT00005006]
@en